ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has further improved its feasibility, protocol optimization and patient recruitment capabilities through the use of TriNetX.
TriNetX is a research network and technology platform connecting ICON to the Electronic Medical Record (EMR) systems of a rapidly expanding network of healthcare organizations representing over 57 million patient lives globally. Through TriNetX, ICON is conducting real-time feasibility reviews by analyzing patient populations with search criteria across multiple data points and assessing the inclusion and exclusion criteria that have the most impact on patient recruitment. Each data point in the TriNetX system can be traced to healthcare organizations who have the ability to identify individual patients, enabling ICON to develop virtual patient cohorts that can be found in real-world clinical trial settings. ICON incorporates the use of EMRs in all new client studies and has already conducted over 300 feasibility reviews utilizing TriNetX across multiple therapeutic areas.
The use of TriNetX is another example of ICON’s leadership in applying targeted technology to help customers reduce the time and cost of their development programs through more accurate patient identification and faster patient recruitment. It follows ICON’s application of cognitive computing capabilities to clinical trial feasibility and patient recruitment. ICON’s ability to recruit patients is also strengthened through a wholly owned site network—PMG Research—with access to over 2 million active patient lives, as well as site partnerships with clinical research sites at healthcare systems and community physician practices all over the world.
ICON’s Chief Operating Officer Dr. Steve Cutler, said, “Access to EMR systems offers new opportunities for more efficient selection of sites and patient recruitment. TriNetX offers robust query and analytics tools that enable real-time analyses of patient populations which are helping our customers design better protocols, select the right sites and recruit patients faster. ICON’s use of TriNetX is a further example of our commitment to deploy industry-leading technologies that help customers overcome complex clinical development challenges.”
“ICON is leveraging the health research network to help pharmaceutical, biotechnology and medical device clients bring new therapies to market faster. TriNetX is pleased to support a world leader improving the efficiency of drug development,” said Gadi Lachman, CEO, TriNetX.
